Frontier Medicines

Frontier targets undruggable cancer proteins using ML and chemoproteomics to develop inhibitors like pan-KRAS, KRAS G12C, and P53 programs.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2019
Frontier Medicines Hover Image